|
Hbm Holdings Limited is a biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology, metabolism, and the central nervous system. The company operates through three core pillars: Harbour Therapeutics, which advances a global portfolio of transformative therapeutics; Harbour Medical, which leverages regional clinical development capabilities; and Nona Biosciences, which provides open access to the group's technologies and expertise. Its proprietary Harbour Mice® platform generates fully human monoclonal antibodies in both conventional and heavy chain-only formats, supporting the development of HBICE® bispecific antibodies and HCAb PLUS™ multi-specific medicines. The company also utilizes the Hu-mAtrIx™ AI platform to power a fully human Generative AI HCAb Model. Hbm Holdings serves global markets through internal research and development, strategic collaborations for co-discovery and co-development, and technology licensing. It maintains R&D centers in China, the United States, and Europe, and partners with academic institutions and pharmaceutical companies to address unmet medical needs. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage harbourbiomed.com |
| Sector Healthcare | IR page harbourbiomed.com/investor | |
|
Tags
antibody therapeutics, immunology, oncology, metabolism, central nervous system, bispecific antibodies, generative ai, transgenic mice, clinical development, technology licensing, Harbour Therapeutics, Harbour Medical, Nona Biosciences, Harbour Mice, HBICE, HCAb PLUS, Hu-mAtrIx, Harbour BioMed-AstraZeneca Innovation Lab
|
Press page harbourbiomed.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 8.57B |
| Market cap (USD) | $ 1.092B |
| P/E | 10.95 |
| PEG | — |
| P/BV | 2.38 |
| P/S | 6.10 |
| P/OCF | 205.03 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.44% |
| Returns | |
|---|---|
| ROE | 37.2% |
| ROI | 21.6% |
| ROIC | 21.6% |
| Profit margin | 57.8% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 16.0% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 33 |
| Quality score | 25.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Press releases from the company's own website, newest first.
- Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer.
- Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026.
- Financing led by RA Capital Management, joined by Canaan Partners, Forbion and other investors.
Cambridge, MA, Rotterdam, NL, Shanghai**, CN** — September 9**, 202****6**
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that Solstice Oncology, its partner company, has launched with a $225 million Series A financing led by RA Capital Management, with participation from Canaan Partners, Forbion and other investors. Solstice is a clinical-stage immuno-oncology company focused on treating cancer earlier, in the neoadjuvant setting.
Solstice is advancing its lead candidate porustobart, a differentiated, second-generation, Fc-enhanced cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, across two clinical indications, one in microsatellite-stable (MSS) colon cancer and a second, undisclosed indication. Its Phase 2 trial is evaluating porustobart in combination with pembrolizumab in the neoadjuvant setting for the treatment of MSS clinical stage II-III colon cancer, the indication with the largest segment of colon cancer patients, which has yet to benefit from immunotherapy.
Porustobart was discovered and developed by Harbour BioMed. In February 2026, Harbour BioMed entered into a license agreement and equity partnership with Solstice Oncology for the exclusive development and commercialization of porustobart (also known as HBM4003 in Harbour BioMed's pipeline) outside Greater China, enabling the advancement of the program globally.
In a Phase 2 clinical study conducted by Harbour BioMed, porustobart in combination with tislelizumab, a PD-1 inhibitor, demonstrated a 30% objective response rate (7 of 23 patients) in late-line patients with MSS metastatic colorectal cancer without liver metastases, with responses showing encouraging durability. The median duration of response was 8.4 months, and porustobart demonstrated a favorable safety profile supporting its continued clinical development. These findings provide clinical support for further evaluating porustobart in combination with PD-(L)1 blockade and in earlier lines of treatment, including the neoadjuvant setting.
"We are pleased to see Solstice Oncology launch with strong support from leading investors and advance porustobart into the neoadjuvant setting," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "As the originator of porustobart and a partner of Solstice, we look forward to supporting the continued development of this differentiated CTLA-4 antibody and exploring its potential to benefit patients worldwide."
"We believe the greatest opportunity in oncology lies in treating disease earlier, in the neoadjuvant setting, when the tumor is still present, the immune system is still intact, and disease hasn't yet hardened its resistance to treatment," said Caroline Loew, PhD, CEO of Solstice Oncology. "Treating patients early with an immuno-oncology combination therapy like the one we are evaluating in our Phase 2 trial could allow the immune response to act systemically, reaching micrometastatic disease well beyond the primary tumor, which is where we see the greatest opportunity to improve cure rates and long-term survival. Since founding the company in February, our team has moved with the speed and discipline this opportunity demands, filing and clearing an IND and now advancing directly into a Phase 2 trial, for which we anticipate data in the second half of 2027."
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
About Solstice Oncology
Solstice Oncology is a clinical-stage immuno-oncology company built around the neoadjuvant treatment setting, the point in a patient's disease course where the company believes the opportunity to improve cure rates and long-term survival is greatest. Founded in February 2026, Solstice is led by a team with decades of experience building and advancing successful immunotherapy drugs in oncology. The company is advancing porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, across two clinical indications: a Phase 2 study in combination with pembrolizumab in the neoadjuvant setting for clinical stage II-III MSS colon cancer, and a second, undisclosed clinical indication. Solstice's initial investors include RA Capital, Canaan Partners, and Forbion. For more information, visit www.solsticeoncology.com .
PREV:
There are no more articles above...
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
- The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing.
- HBM9378/WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbations. These effects were rapid and sustained through Week 24 after a single dose of HBM9378/WIN378.
- HBM9378/WIN378 was well tolerated with favorable safety results — there were no treatment-related serious adverse events, withdrawals, or discontinuations; adverse events were balanced between active arms and placebo, with low rates of injection site reactions and anti-drug antibodies.
- The first Phase 3 study of HBM9378/WIN378 has been initiated evaluating two twice-yearly doses. A second Phase 3 trial is planned to begin in the first half of 2027.
Cambridge, MA, Rotterdam, NL, Shanghai**, CN** — September 8**, 202****6**
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology, and other areas, today announced that its partner, Windward Bio, has reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial, which evaluates twice-yearly dosing of HBM9378/WIN378 in asthma.
HBM9378/WIN378 is a novel fully human, ultra-long-acting monoclonal antibody with a unique binding mode to inhibit thymic stromal lymphopoietin (TSLP). It was engineered for improved potency, extended half-life and silenced effector function. It is the only known investigational drug that blocks TSLP signaling by binding to two different sites on TSLP, interfering with the binding of TSLP to both of its co-receptors on the cell surface of epithelial cells.
POLARIS-1 is an operationally seamless, global Phase 2/3 study. The Phase 2 portion of the study is a 48-week, randomized, double-blind study evaluating three dose levels of HBM9378/WIN378 against placebo. It is designed to evaluate the pharmacokinetics, safety, immunogenicity, and pharmacodynamic activity of HBM9378/WIN378 in patients with uncontrolled moderate-to-severe asthma. The study also evaluates the effects of HBM9378/WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total of 147 patients, exceeding the initial enrollment target of 120 patients, with the interim analysis conducted on the first 98 patients.
The interim analysis demonstrated the following at Week 24 after a single dose of HBM9378/WIN378:
- Dose-dependent mean increases in FEV1 of up to 174 mL (placebo-adjusted mean increase up to 256 mL, p=0.033).
- Dose-dependent mean reductions in FeNO of up to 24 ppb (or -43% change, p=0.006).
- Reductions in mean blood eosinophil count (EOS) of up to 200 cells/µL (or -51% change, p<0.0001).
- Near maximal effects seen as early as Week 2 and sustained through Week 24.
Notes: FEV1 (forced expiratory volume in one second) is a key measure of lung function. FeNO (fractional exhaled nitric oxide) and EOS are key markers of inflammation that correlate with exacerbations.
HBM9378/WIN378 was well tolerated with favorable safety results, and there were no treatment-related serious adverse events, withdrawals, or discontinuations observed as of the cut-off date. Adverse events were balanced between active arms and placebo. Less than 1% of participants experienced injection site reactions, and 2% developed anti-drug antibodies (ADAs), a measure of immunogenicity. ADAs had no impact on the pharmacology of HBM9378/WIN378. The results of the interim analysis and population pharmacokinetic modeling support the potential of twice-yearly dosing of HBM9378/WIN378.
"We are very encouraged by the positive Phase 2 results of HBM9378/WIN378 and its continued progression into Phase 3 development," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. "HBM9378/WIN378 is an ultra-long-acting fully human monoclonal antibody against TSLP generated from our H2L2 Harbour Mice® platform. The significant and sustained improvements in lung function and airway inflammation observed with a single dose, together with its potential for twice-yearly dosing, further reinforce the therapeutic potential of this molecule. We are fully confident in the clinical potential of this novel biotherapeutic."
Two twice-yearly doses have been selected for the Phase 3 portion of POLARIS-1, which is designed to evaluate the effect of HBM9378/WIN378 on annualized asthma exacerbation rate and other key efficacy measures in patients with severe asthma. The Phase 3 portion of the study has been initiated by Windward Bio who plans to begin a second Phase 3 study, POLARIS-2, in the first half of 2027. Data from the Phase 2 portion of POLARIS-1 will be presented at an upcoming medical congress.
About POLARIS-1 Study
POLARIS-1 (NCT07120503) is an operationally seamless, global Phase 2/3 study of HBM9378/WIN378 in adults with uncontrolled asthma conducted by Windward Bio. The Phase 2 portion is a randomized, double-blind study evaluating three dose levels of HBM9378/WIN378 administered subcutaneously against placebo, with primary objectives of characterizing pharmacokinetics, safety, immunogenicity and pharmacodynamic activity, as well as informing dose selection for Phase 3. The Phase 3 portion is evaluating two twice-yearly doses of HBM9378/WIN378 against placebo, with a primary endpoint of annualized asthma exacerbation rate in patients with severe asthma.
About HBM9378/WIN378
HBM9378/WIN378 is a novel fully human, ultra-long-acting monoclonal antibody with a unique binding mode to inhibit thymic stromal lymphopoietin (TSLP). This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. HBM9378/WIN378 was engineered for improved potency, extended half-life and silenced effector function. It is the only known investigational drug that blocks TSLP signaling by binding to two different sites on TSLP, interfering with the binding of TSLP to both of its co-receptors on the cell surface of epithelial cells. Phase 2 interim results support the potential of twice-yearly dosing. HBM9378/WIN378 produced significant, sustained and dose-dependent increases in FEV1, a measure of lung function, together with significant and sustained reductions in FeNO and blood eosinophils — key markers that correlate with asthma exacerbations. HBM9378/WIN378 is being evaluated in the global Phase 2/3 POLARIS-1 study in asthma and the Phase 2 SIRIUS study in COPD, with a second pivotal Phase 3 asthma trial, POLARIS-2, planned to begin in the first half of 2027. HBM9378/WIN378 (also known as SKB378) started as a co-development project jointly conducted by Harbour BioMed and Kelun-Biotech, with both parties equally sharing global rights. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for this molecule from Harbour BioMed (also known as HBM9378) and Kelun-Biotech (also known as SKB378).
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
About Windward Bio
Windward Bio is a clinical-stage biotechnology company with deep discovery, development and commercial expertise, developing ultra-long-acting antibodies for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. The Company is advancing a pipeline of potentially differentiated biologics targeting clinically validated molecular pathways, with the goal of improving clinical outcomes while reducing treatment burden through less frequent dosing. Windward Bio's lead program is WIN378, a novel fully human monoclonal antibody engineered for improved potency, extended half-life and silenced effector function, targeting TSLP. WIN378 is in clinical development for asthma and COPD. The Company's second program is WIN027, an ultra-long-acting, humanized bi-specific antibody targeting TSLP and IL-13 in development for respiratory and dermatologic diseases. Windward Bio was founded in 2024 and is headquartered in Basel, Switzerland, with operations in the United States. For more information, visit www.windwardbio.com .
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai, CN — September 6, 2026
Today, shares of Harbour BioMed (the "Company"; HKEX: 02142.HK) were officially included in the eligible shares list of the Stock Connect. Effective immediately, qualified investors in mainland China can directly invest in the Company's shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs.
This inclusion in Stock Connect marks a significant milestone, reflecting that the Company's market capitalization has steadily surpassed the HK$10 billion threshold, officially positioning it among the large- and mid-cap biopharmaceutical companies in the Hong Kong stock market. This achievement underscores the capital market’s positive recognition of the Company's growth prospects, R&D momentum, and strategic execution, while also serving as a strong testament to its long-term value being steadily acknowledged in the secondary market.
In the first half of 2026, the Company recorded total revenue of approximately US$122.5 million, representing a year-over-year increase of 20.9%. Adjusted net profit reached approximately US$71.6 million, marking seven consecutive profitable half-years and confirming that Harbour BioMed has officially entered a phase of "normalized profitability," further validating the sustainability and replicability of the business model underpinning this platform-based biopharmaceutical group. Cash and cash equivalents stood at approximately US$359.2 million as of June 30, 2026. The Company maintains strong financial resources and flexibility to support its strategic execution.
In terms of the pipeline, the Company has built a portfolio of nearly 30 differentiated drug candidates across multiple therapeutic areas, including immunology, oncology, metabolism, and the central nervous system (CNS), with several molecules having already entered clinical trials or regulatory submission stages. Batoclimab (HBM9161), the Company's lead asset, has been submitted for Biologics License Application (BLA) review and is positioned as a potential blockbuster therapy for multiple autoimmune indications. Porustobart (HBM4003), the first fully human heavy-chain-only antibody which entered clinical development globally, has demonstrated positive efficacy and safety profiles in multiple monotherapy and combination studies targeting advanced solid tumors. HBM9378, a next-generation ultra-long-acting anti-TSLP monoclonal antibody, has recently achieved several key milestones. Our partner, Windward Bio, has initiated the Phase II SIRIUS study for HBM9378 for the treatment of COPD and completed dosing of the first patients. Meanwhile, initial readouts from the Phase II/III POLARIS study in asthma are expected in the second half of 2026, with the first Phase III study of HBM9378 in asthma is expected to begin in the fourth quarter of 2026.
Additionally, continued progress on innovative molecules such as HBM7575, HBM7020, and LET003 underscores the Company's capabilities in target selection and molecular design.
To date, the Company has propelled its core pipeline into the global market through a series of out-licensing transactions. Notable examples include the out-licensing of ex-China rights for HBM9378 to Windward Bio; an ex-China licensing agreement for HBM7020 (BCMA×CD3) with Otsuka Pharmaceutical; a license agreement and equity partnership with Solstice Oncology for HBM4003; and a licensing and collaboration agreement with AstraZeneca for HBM7022 (Claudin18.2×CD3). These partnerships strongly demonstrate the Company's strategic execution capabilities in unlocking the global value of its pipeline and accelerating clinical translation through flexible and diversified collaboration models.
Leveraging its industry-leading Harbour Mice® fully human antibody technology platform, Harbour BioMed has established itself as a leading force in biotech BD partnerships. Its subsidiary, Nona Biosciences, has further built out four major technology engines—a bispecific/multispecific antibody platform, an XDC platform, a CAR-T platform, and an AI-driven drug discovery platform—giving it a foundational edge in the ongoing innovation wave that is moving the field from antibodies to antibody-plus, and from simple molecules to complex modalities.
To date, the Company has entered into long-term strategic partnerships with leading multinational pharmaceutical companies, including AstraZeneca, Otsuka Pharmaceutical, Bristol Myers Squibb (BMS), and Pfizer, with cumulative global collaboration deal value exceeding US$13 billion. The partnership with AstraZeneca stands out as a particularly representative example: the relationship has evolved from a single-product license into a multi-dimensional framework encompassing R&D collaboration, equity investment, and a joint laboratory initiative—marking a significant value leap from product-level licensing to platform-level strategic partnership. This collaboration serves as a benchmark paradigm for how innovative biotechnology companies in China can establish deep, strategic collaborations with top-tier multinational companies (MNCs).
Meanwhile, the Company has been actively driving the deep integration of AI into drug R&D. In October 2025, Harbour BioMed unveiled its first fully human AI HCAb generation and screening model powered by the Hu-mAtrIx™ platform, establishing a closed loop of "AI design – intelligent screening – wet-lab validation" that significantly enhances the efficiency and precision of antibody discovery. In 2026, LET003, a next-generation anti-ACVR2A/2B monoclonal antibody developed using the Hu-mAtrIx™ platform, delivered superior preclinical data. Subsequently, the Company entered into a strategic collaboration with BioMap to co-found MegaStream TechBio, integrating a proprietary ecosystem of exclusive datasets × purpose-built large models × large-scale innovative pipeline portfolio into an AI-powered R&D engine.
This inclusion in the Stock Connect program will further broaden the Company's investor base, attract greater participation from southbound capital, effectively enhance stock liquidity and market visibility, and facilitate a more comprehensive discovery and recognition of the Company's value in the capital markets. Besides, a more diversified investor composition will further strengthen the Company's presence in the international capital markets, fostering a more stable and dynamic capital ecosystem to support its long-term growth.
Dr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour BioMed, commented: "The inclusion of our shares in the Stock Connect program marks an important capital markets milestone for Harbour BioMed. It strongly reflects the market's recognition of our business momentum, innovation capabilities, and corporate governance, while also positioning us to attract greater interest and support from long-term value investors. Going forward, we remain steadfast in our commitment to pioneering innovation, accelerating clinical advancement of our core pipeline, and executing on our global partnership strategy, as we strive to deliver strong performance that upholds the trust of our shareholders."
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
NEXT:
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai**, CN** — August 27**, 202****6**
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced its interim results for the six months ended June 30, 2026.
Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "In the first half of 2026, Harbour BioMed continued to advance our Phase 3.0 strategy, with meaningful progress across all three integrated growth engines. We continued to advance the global value of our mid- to late-stage innovative assets, further strengthened our technology platform capabilities, particularly in AI-driven next-generation antibody discovery capability, and continued to deepen long-term strategic partnerships with leading global pharmaceutical companies. The three growth engines are mutually reinforcing, creating stronger connections among our technology platforms, innovative pipeline and global partnership network, and continuously translating these capabilities into long-term value.
We also achieved a landmark milestone in intellectual property protection. Our historic and decisive victory in the U.S. patent litigation not only reaffirmed the validity of the intellectual property underlying our core antibody discovery platforms, but also demonstrated our firm commitment to protecting our core innovations and building global competitive advantages.
In terms of talent and organizational development, we have further streamlined our global management and scientific teams over the past six months. We have appointed experienced industry leaders, experts across multiple therapeutic areas, and world-renowned scientific advisors, who provide enhanced support for R&D innovation, portfolio strategy, and global collaboration.
Looking ahead, we will continue to drive strategic execution across our three integrated growth engines, accelerate the advancement of high-potential innovative assets into mid- to late-stage clinical development, unlock the global value of our technology platforms and pipeline, and further expand high-quality global partnerships. We are steadily advancing toward our 2028 vision of becoming a globally leading platform-based biopharmaceutical group."
202****6 Interim Financial Highlights: Strong Revenue Growth and Sustained Profitability for Seven Consecutive Half-Years
- Total revenue reached US$122.5 million, representing a 20.9% year-over-year increase, primarily driven by continued strategic collaborations with global multinational pharmaceutical companies, newly established out-licensing agreements for innovative products, and strong business growth of Nona Biosciences;
- Profit for the period reached US$64.9 million, and adjusted net profit for the period[1] was approximately US$71.6 million, marking seven consecutive profitable half-years and confirming that Harbour BioMed has officially entered a phase of "normalized profitability," further validating the sustainability and replicability of the business model underpinning this platform-based biopharmaceutical group;
- Cash and cash equivalents stood at approximately US$359.2 million as of June 30, 2026. The Company maintains strong financial resources and flexibility to support its strategic execution.
[1] Adjusted items of profit are mainly from share-based compensation expenses and other one-time expenses.
Multiple Milestones Achieved, Unlocking the Global Value of Mid- to Late-Stage Innovative Assets
Harbour BioMed continued to advance a differentiated portfolio across immunology, oncology, obesity and metabolic diseases, and central nervous system (CNS) disorders, with multiple high-potential programs progressing toward key clinical development milestones.
Key programs in mid- to late-stage clinical development:
Batoclimab (HBM9161) is the first anti-FcRn monoclonal antibody to have completed Phase I to pivotal trials in China. The Biologics License Application (BLA) for the treatment of generalized myasthenia gravis (gMG) was accepted by China's National Medical Products Administration (NMPA) in July 2024 and is currently under review. Batoclimab has the potential to be a breakthrough treatment option for a wide range of autoimmune diseases.
HBM9378 is an ultra-long-acting fully human monoclonal antibody against TSLP generated from the H2L2 Harbour Mice® platform, engineered to achieve an extended half-life and effector silencing with subcutaneous administration. In March 2026, the Company published first-in-human Phase I trial results in the peer-reviewed journal Drug Design, Development and Therapy, demonstrating favorable safety and an extended half-life (mean T1/2: 55.0–65.8 days).
In January 2025, it was announced that the Company and Kelun-Biotech entered into an exclusive license agreement with Windward Bio, under which Windward Bio was granted an exclusive license for the research, development, manufacturing and commercialization of HBM9378 globally (excluding Greater China and several Southeast and West Asian countries). In July 2025, our partner Windward Bio launched the Phase II/III POLARIS clinical study in asthma, with initial data expected in the second half of 2026 and the first Phase III study of HBM9378 in asthma is expected to begin in the fourth quarter of 2026. In June 2026, Windward Bio dosed the first patients in the Phase II SIRIUS study in COPD.
Note: HBM9378 is known as SKB378 in Kelun-Biotech's pipeline and WIN378 in Windward Bio's pipeline.
Porustobart (HBM4003) is a next-generation, fully human heavy-chain-only anti-CTLA-4 antibody discovered and developed using the HCAb Harbour Mice® platform. It is also the first fully human heavy-chain-only antibody which entered clinical development globally. In October 2025, the Company published positive Phase II data in combination with tislelizumab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Of the 23 evaluable patients, the objective response rate (ORR) is 34.8%, disease control rate (DCR) is 60.9%, and 12-month overall survival (OS) Rate is 84%. In February 2026, the Company entered a license agreement and equity partnership with Solstice Oncology, a clinical stage biotechnology company established by a syndicate of major venture capital investors, for the exclusive development and commercialization of HBM4003 outside Greater China. Following this agreement, HBM4003 made meaningful global development progress during the reporting period.
HBM7575 is an ultra-long-acting bispecific antibody targeting TSLP and an undisclosed antigen, with a dual mechanism of action. On one hand, by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells. On the other hand, binding to and blocking the undisclosed target generates a synergistic effect, with the potential to achieve broader control of inflammation compared to single-target approaches. HBM7575 has been engineered to allow for longer dosing intervals and a convenient subcutaneous route of administration. Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of more than three months, positioning it as a potential best-in-class therapy.
In March 2026, an IND application for HBM7575 for the treatment of atopic dermatitis was approved by the NMPA, and the first participant has been dosed in a Phase 1 clinical study. In July 2026, an IND application for HBM7575 for the treatment of asthma was approved by the NMPA.
Note: HBM7575 is known as SKB575 in Kelun-Biotech's pipeline. According to the collaboration agreement between Harbour BioMed and Kelun-Biotech, HBM7575 is led by Kelun-Biotech in its design, global development and commercialization, with Harbour BioMed participating in the investment and development of this asset and sharing the benefits as agreed.
Key products in the next-generation innovation portfolio include:
HBM2001 is a potent TL1A×IL-23p19 bispecific antibody generated using the proprietary HBICA® bispecific technology and Harbour Mice® platform, offering a differentiated mechanism to address both inflammatory and fibrotic pathways in inflammatory bowel disease. In April 2026, HBM2001 obtained FDA IND clearance to commence a Phase I trial in the United States. In July 2026, HBM2001 obtained NMPA IND clearance to commence a Phase I trial in China.
HBM7020 is a BCMA×CD3 bispecific antibody generated using the HBICE® technology and Harbour Mice® platform. Following the global strategic collaboration with Otsuka Pharmaceutical established in June 2025, HBM7020 continued to advance product development as planned during the reporting period, with the Phase I clinical trial expected to initiate overseas in the second half of the year.
HBM7004 is a novel B7H4×CD3 bispecific antibody demonstrating strong anti-tumor efficacy and favorable safety in preclinical studies. In May 2026, the FDA cleared the IND application for HBM7004, enabling the initiation of a first-in-human Phase I clinical trial in the United States. In August 2026, the NMPA approved the IND application for HBM7004 for the treatment of advanced solid tumors.
LET003 is the first ACVR2A/2B dual-target blocking antibody developed using the Hu-mAtrIx™ artificial intelligence platform. ACVR2A and ACVR2B play critical roles in regulating muscle-fat metabolic homeostasis. Extensive preclinical and clinical studies have demonstrated that combining receptor-blocking antibodies targeting ACVR2A/2B with GLP-1-based weight loss therapies can further reduce body fat while effectively mitigating lean mass loss. In May 2026, the Company announced promising preclinical data for LET003. Data showed that LET003 exhibited superior pharmacokinetic characteristics compared to multiple competitor molecules. When combined with semaglutide, LET003 significantly enhanced fat reduction while effectively preserving lean mass. In addition, LET003 achieved lean mass-promoting effects at lower dose level comparable to bimagrumab at higher dose level, highlighting its potential to become a best-in-class therapy for obesity treatment. LET003 has advanced to the IND-enabling stage, with an IND submission expected in the third quarter of 2026.
CNS Disease Programs: the Company is advancing a next-generation CNS pipeline focused on Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Multiple programs are in preclinical development, with NEU2005 expected to file an IND application in the first half of 2027.
HBM9013 (CRH Neutralizing Antibody): HBM9013/HAT001 is a potent and selective anti-CRH neutralizing antibody for various disorders including congenital adrenal hyperplasia (CAH). In February 2025, HBM Alpha Therapeutics (HBMAT), an innovative biotechnology company incubated by the Company, announced a strategic collaboration and license agreement with Spruce Biosciences. Under the agreement, Spruce Biosciences gains exclusive global rights, excluding Greater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and commercialize HBM9013/HAT001.
AI-Driven Next-Generation R&D Infrastructure Continues to Enhance Innovation Efficiency
Technology platform innovation remains a core pillar of Harbour BioMed's long-term strategy. The Company continues to integrate its Hu-mAtrIx™ AI platform with core antibody technology platforms including Harbour Mice®, further embedding AI capabilities across the antibody drug discovery and development process to enhance R&D efficiency. The Company has established a technology platform matrix spanning a broad range of therapeutic modalities, including bispecific and multi-specific antibodies, T-cell engagers (TCEs), antibody-drug conjugates (ADCs) and more, providing technological support for the development of innovative therapies across multiple therapeutic areas.
During the Reporting Period, the Company continued to enhance the Hu-mAtrIx™ AI platform, strengthening capabilities including a fully human heavy-chain-only antibody model based on large-scale next-generation sequencing (NGS) HCAb sequence data, de novo design model, developability prediction, in silico screening and AI-guided engineering. The Company also continued to integrate AI with wet-lab experimental validation to explore more efficient approaches to drug discovery and development.
AI-enabled R&D capabilities are increasingly translating into tangible innovation. In May 2026, the Company announced positive preclinical data for LET003, its first next-generation candidate developed using the Hu-mAtrIx™ AI platform. The results showed promising pharmacokinetic characteristics, while combination with semaglutide significantly enhanced fat reduction and effectively preserved lean mass, highlighting its potential to become a best-in-class therapy for obesity.
Building on these capabilities, the Company is also exploring new R&D models powered by AI. In June 2026, Harbour BioMed entered into a long-term global strategic partnership with BioMap and jointly initiated MegaStream TechBio, focused on AI-driven discovery and development of complex biologics. MegaStream will integrate proprietary datasets, purpose-built large models, innovative pipeline assets and an intelligent dry-wet closed-loop R&D platform, further advancing AI-enabled discovery and development of next-generation complex biologics.
Deepening Long-Term Platform-Based Strategic Partnerships to Expand the Global Innovation Ecosystem
Leveraging its differentiated technology platforms and R&D capabilities, Harbour BioMed continued to establish multi-level partnerships with leading global pharmaceutical companies and biotechnology companies, and through diversified collaboration models including strategic collaboration, co-development, product licensing, technology licensing and technology services, has built a complete R&D chain spanning early discovery, clinical development and commercialization.
In December 2025, the Company entered into global strategic collaboration and license agreement with Bristol Myers Squibb (BMS) to discover and develop next-generation multi-specific antibodies. Under the terms of the agreement, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion, along with tiered royalties should BMS elect to advance all potential programs.
In the first half of 2026, the Company entered into a license agreement and equity partnership with Solstice Oncology for HBM4003. Under the terms of the agreement, the Company received upfront consideration valued at over $105 million and is eligible for additional development, regulatory and commercial milestones up to approximately $1.1 billion, plus tiered royalties on net sales outside Greater China. The Company also participated in Windward Bio's US$165 million financing and continued to deepen collaboration with global partners in antibody discovery, CNS delivery and other innovative areas.
Additionally, Nona Biosciences, the wholly owned subsidiary of Harbour BioMed, entered into a multi-target antibody discovery collaboration with Link Cell Therapies in January 2026, leveraging Nona's proprietary fully human HCAb Harbour Mice® platform and its innovative direct CAR-function-based HCAb library screening platform, NonaCarFx™, to generate novel CAR-T cell therapy candidates.
In June 2026, Nona Biosciences entered into a strategic collaboration with Lonza. This collaboration leverages Nona's proprietary Harbour Mice® fully human HCAb platform to discover and develop next-generation single-domain antibody-based blood-brain barrier (BBB)-crossing technologies. Leveraging the platform's proven ability to generate fully human HCAbs and VHH binders with exceptional affinity and developability, the partnership aims to establish a best-in-class BBB-crossing technology capable of enabling the delivery of a diverse range of therapeutic modalities into the central nervous system (CNS) and unlocking new opportunities in CNS drug development and technology licensing. Under the terms of the agreement, Nona is entitled to receive upfront and option payments from Lonza. The parties will also share revenues generated from future licensing agreements pursuant to the collaboration.
This multi-level approach creates a resilient, scalable business model designed to generate long-term, predictable value.
Continuously Strengthening Innovation and Intellectual Property Barriers, Further Enhancing Global Team Capabilities
Alongside continued progress in pipeline development and business collaborations, Harbour BioMed further strengthened the technology, intellectual property and talent foundation supporting its long-term innovation.
As of June 30, 2026, the Company had filed 706 patent applications, including 19 invention patents granted by the China National Intellectual Property Administration, with 521 patent applications under review. At the same time, the Company continued to strengthen its global management and scientific team by bringing together experienced industry leaders, experts across multiple therapeutic areas, and world-renowned scientific advisors, further enhancing its professional capabilities in R&D innovation, asset strategy, external innovation and global collaboration.
During the Reporting Period, the Company achieved a decisive victory in its core U.S. patent litigation. The jury upheld the validity of the relevant core patent, found Amgen's infringement to be willful and awarded Harbour BioMed US$20.20 million in damages – the full amount requested. The findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million. The verdict further validated the validity and enforceability of the intellectual property underlying the Company's core antibody discovery platform and provided important support for the Company's continued expansion of global collaborations and platform value.
Accelerating 2026 Strategic Execution Toward the 2028 Vision
Looking ahead, Harbour BioMed will continue to drive business growth through its three integrated growth engines and steadily advance toward its 2028 vision of becoming a globally leading platform-based biopharmaceutical group.
In the second half of 2026, the Company expects to advance multiple high-potential programs toward key clinical milestones, including the initial data readout from the Phase II/III POLARIS study of HBM9378/WIN378, as well as potential significant milestones for porustobart (HBM4003). The Company will also continue to accelerate next-generation innovative candidates into clinical development and advance its differentiated pipeline across immunology, oncology, obesity and metabolic diseases, and central nervous system disorders. Additionally, the Company will actively explore diverse collaboration opportunities and further strengthen its position in the global innovation ecosystem by expanding strategic partnerships with global partners, continuing to bring transformative biotherapeutics to patients worldwide.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
PREV:
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai**, CN** — August 27**, 202****6**
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Mr. Youchen Chen, Chief Financial Officer, and Dr. Ian Y. Liu, Senior Vice President and Global Head of Legal, as Executive Directors of the Company, effective immediately. The appointments further strengthen the alignment between the Company's Board of Directors and management team, providing strong leadership support for the Company's global strategic execution and sustainable growth.
Mr. Youchen Chen currently serves as Chief Financial Officer of Harbour BioMed and is based in Hong Kong and Shanghai. As a key executive of the Company's management team, he is responsible for overseeing the Company's global financial strategy, capital market strategy, investor relations, as well as strategic ecosystem development and investment initiatives. Mr. Chen joined Harbour BioMed in 2023 and has progressively assumed key responsibilities across finance, strategy, investor relations and corporate development. He has played a pivotal role in leading a number of landmark strategic transactions with global partners.
Mr. Youchen Chen has nearly 15 years of experience spanning global capital markets, financial management, and business development in the biopharmaceutical industry. Prior to joining Harbour BioMed, he served as Chief Financial Officer of a clinical-stage radiopharmaceutical startup. Before that, he served as Vice President at Credit Suisse China Investment Banking and Capital Market team, where he provided strategic and capital markets advisory services to healthcare and tech companies across Greater China regions. Prior to rejoining Credit Suisse China, he worked as Head of Corporate Finance at Yidu Tech (2158. HK) and Audit Assistant Manager at KPMG. Mr. Chen holds a bachelor's degree in law from Fudan University and an MBA from the McDonough School of Business at Georgetown University.
Dr. Ian Y. Liu currently serves as Senior Vice President and Global Head of Legal at Harbour BioMed and is based in the United States. He oversees the Company's global legal affairs, with a focus on ensuring legal and regulatory compliance across its businesses and transactions. He also leads the Company's global intellectual property strategy and oversees major litigation matters.
Dr. Liu has more than 20 years of experience spanning global legal and government affairs, as well as biopharmaceutical R&D and operations. Prior to joining Harbour BioMed, he worked at internationally recognized law firms, including Finnegan, Henderson, Farabow, Garrett & Dunner, LLP and K&L Gates LLP, where he gained extensive experience in patent applications, litigation, and due diligence. In the corporate legal affairs sector, he previously served as Head of Legal and Government Affairs at Simcere Pharmaceutical, and as Global Head of Legal and Head of U.S. Operations at BREAS, a subsidiary of Fosun Pharma, where he demonstrated strong expertise in navigating complex legal matters, commercial negotiations, and international operations. Dr. Liu holds a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a J.D. from Suffolk University Law School.
Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed, commented: "We are very pleased to welcome Mr. Youchen Chen and Dr. Ian Y. Liu to the Company's Board of Directors. Their outstanding achievements and deep expertise in their respective fields have already made a significant impact on our Company. The appointment of both as Executive Directors is a strong recognition of their professional capabilities and leadership contributions. We are confident that in their new roles, they will bring even greater diversity and depth of insight to the Company's strategic decision-making, further propelling Harbour BioMed to new heights in global innovation and sustainable growth."
Mr. Youchen Chen, Chief Financial Officer and Executive Director of Harbour BioMed, stated: "It is a great honor to further participate in corporate governance and strategic decision-making in my new capacity as Executive Director. Since joining Harbour BioMed, I have had the privilege of witnessing and contributing to the Company's rapid global development and the execution of multiple key strategic partnerships. In the future, I look forward to working closely with the Board and the management team to further optimize the Company's financial and capital market strategies and drive long-term value creation, while contributing to Harbour BioMed's ambitious goal of becoming a leading global platform-based biopharmaceutical group by 2028."
Dr. Ian Y. Liu, Senior Vice President, Global Head of Legal, and Executive Director of Harbour BioMed, said: "It is a true privilege to continue serving Harbour BioMed as an Executive Director. The Company has always stood at the forefront of innovative drug discovery and development. In the areas of global legal compliance and intellectual property strategy, I will continue to leverage my professional expertise to provide solid legal protection and strategic support for the Company's globalization efforts and innovative growth."
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai**, CN** — August 18**, 202****6**
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors.
HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Company's HBICE® platform. This bispecific antibody is designed to provide a differentiated approach to cancer immunotherapy with the potential to enhance both efficacy and safety. The development of HBM7004 further demonstrated the HBICE® platform's versatility and plug-and-play advantages. In preclinical studies, HBM7004 demonstrated an intratumor B7H4-dependent T cell activation manner. In multiple animal models, HBM7004 showed strong anti-tumor efficacy, remarkable in vivo stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window.
"We are very pleased to receive NMPA approval of IND application for HBM7004, which marks another important milestone in our commitment to advancing novel immunotherapies for patients with advanced solid tumors," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. "This approval, together with the recent FDA clearance, underscores the strength of our HBICE® platform and its ability to generate differentiated bispecific candidates with promising preclinical profiles. We are now one step closer to bringing HBM7004 into the clinic in China, and we look forward to advancing this program to address the needs of cancer patients with limited treatment options."
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai, CN — August 6, 2026
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. Bob Zhang as President of Metabolic Disease Franchise. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed.
The appointment underscores Harbour BioMed's strategic commitment to building a dedicated metabolic disease franchise and advancing a differentiated pipeline of innovative therapies for obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH)/liver diseases and cardiovascular disorders. As President of the Metabolic Disease Franchise, Dr. Zhang will lead the franchise's strategy and operations, overseeing portfolio development, research and development, organizational growth, strategic collaborations, and NewCo incubation to accelerate the delivery of transformative therapies for patients.
Metabolic diseases represent one of the fastest-growing areas of unmet medical need globally. Cardiovascular diseases remain the leading cause of mortality worldwide, with significant unmet needs persisting despite existing treatments, particularly in areas where metabolic dysfunction is a key underlying driver. Building on its proprietary antibody discovery technologies and growing expertise in metabolic and cardiovascular biology, Harbour BioMed is expanding its investment in these therapeutic areas with the goal of developing next-generation biologics that address the complex mechanisms underlying metabolic and cardiovascular diseases.
Dr. Zhang is a physician-scientist and biotech entrepreneur with more than 20 years of leadership experience in metabolic and liver disease research and development. Prior to joining Harbour BioMed, he served as Co-founder and Chief Executive Officer of Epigenic Therapeutics, Chief Executive Officer of Kunming Biomed International, and Director of Translational Medicine at Sanofi. Throughout his career, he has led drug discovery, translational pharmacology, and early clinical development programs across biotechnology companies, multinational pharmaceutical organizations, and CROs, while also contributing to biotech company formation, strategy, and growth.
"We are delighted to welcome Bob to Harbour BioMed at an exciting stage in our evolution," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. "The establishment of our Metabolic Disease Franchise reflects our long-term commitment to building a robust portfolio of innovative therapies that can make a meaningful difference for patients living with obesity and other metabolic and cardiovascular diseases. Bob brings an exceptional combination of scientific insight, translational expertise, and entrepreneurial leadership. His extensive experience in advancing metabolic and cardiovascular disease programs will be instrumental as we accelerate our pipeline, strengthen strategic partnerships, and translate our scientific innovation into impactful therapies."
"I am excited to join Harbour BioMed at a pivotal time as the Company deepens its commitment to metabolic and cardiovascular diseases," said Dr. Bob Zhang, President of Metabolic Disease Franchise at Harbour BioMed. "Harbour BioMed has built a strong foundation of scientific innovation and proprietary antibody technologies. I look forward to working with the talented team to advance a differentiated pipeline of innovative therapeutics addressing obesity, MASH, and other metabolic disorders, as well as cardiovascular indications, ultimately bringing transformative treatment options to patients worldwide."
Dr. Zhang received his M.D. from Dalian Medical University and his Ph.D. from the University of Sydney, and completed executive management training at CEIBS (China Europe International Business School).
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai, CN — July 27, 2026
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with China National Pharmaceutical Group Co., Ltd. (“Sinopharm”). The two parties will establish the Sinopharm - Harbour BioMed Innovation Consortium (the “Innovation Consortium”) to advance collaborative research and development of innovative biologics.
Under the terms of the agreement, Harbour BioMed and Sinopharm will collaborate across the full research and development lifecycle of innovative biologics, with a strategic focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas. Harbour BioMed will leverage its globally leading Harbour Mice® fully human antibody technology platform and AI-enabled drug discovery capabilities to drive the discovery and optimization of antibody candidates together with Sinopharm. Sinopharm will contribute their expertise in clinical development, large-scale manufacturing and commercialization, and will be responsible for developing commercial-scale manufacturing processes, producing clinical trial materials, and commercializing products arising from the collaboration. The two parties will jointly fund the research and development activities and share product rights in accordance with mutually agreed terms.
"We are delighted to establish this strategic partnership with Sinopharm," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. "Harbour BioMed is committed to becoming a leading platform-driven biopharmaceutical group. Leveraging our globally differentiated Harbour Mice® fully human antibody technology platform and continuously expanding AI-enabled antibody discovery capabilities, we have established strategic collaborations with leading global pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Pfizer. This partnership with Sinopharm represents another important step in advancing our 'platform + pipeline' strategy in China. Sinopharm is a leading pharmaceutical and healthcare group that covers the entire industry chain—from R&D and manufacturing to distribution. With strong R&D capabilities, robust industrial-scale production capacity, proven commercial execution, and an extensive market network, we look forward to deeply integrating the strengths of our technology platform with Sinopharm's full-industry-chain capabilities to jointly accelerate the R&D and accessibility of innovative medicines."
Sinopharm commented: "As the national team in the pharmaceutical and healthcare sector, Sinopharm has always placed scientific and technological innovation at the core of its development strategy and is accelerating the establishment of a new paradigm that synergizes independent innovation with open collaboration. Harbour BioMed is a world-leading platform-driven biopharmaceutical company, equipped with a rare fully human antibody technology platform and AI-powered antibody discovery capabilities that are at the forefront in China. The establishment of an innovation R&D consortium with Harbour BioMed represents a key move by Sinopharm to optimize resource allocation and enhance R&D efficiency. We look forward to both parties fully leveraging our respective strengths in technology, talent, platforms, and industrial chains to jointly advance the R&D and industrialization of innovative drugs, and to provide patients with more high-quality and affordable treatment options."
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
Cambridge, MA, Rotterdam, NL, Shanghai, CN – July 23, 2026
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended June 30, 2026 (the "Reporting Period").
Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, the revenue is expected to range between US$120 million (equivalent to approximately HK$941 million) and US$125 million (equivalent to approximately HK$980 million), representing an increase of approximately 19% to 24% compared with approximately US$101 million for the corresponding period in 2025. The profit for the Reporting Period is expected to range between US$62 million (equivalent to approximately HK$486 million) and US$67 million (equivalent to approximately HK$525 million). Total adjusted profit [1] is expected to range between US$70 million (equivalent to approximately HK$549 million) and US$75 million (equivalent to approximately HK$588 million).
The expected revenue growth and scaled profitability are primarily attributable to:
- Continued strategic collaborations with global multinational pharmaceutical companies, including the potential 10-year long-term strategic collaboration with AstraZeneca and the global strategic collaboration with Bristol Myers Squibb.
- Newly secured out-licensing and collaboration agreements for innovative products, such as the licensing agreement with Solstice Oncology, as well as milestone payments triggered by the advancement of previously out-licensed programs.
- Strong business growth of Nona Biosciences, including revenue generated from antibody transactions and antibody discovery, such as the platform collaboration with Lonza in central nervous system.
With seven consecutive profitable half-years, Harbour BioMed has officially entered a phase of "normalized profitability," further validating the sustainability and replicability of the business model underpinning this platform-based biopharmaceutical group.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: "Our expected profitability in the first half of 2026 marks an important milestone in Harbour BioMed's development and strongly validates our differentiated business model. The value of our proprietary technology platforms is gaining recognition through a growing number of deep strategic partnerships with multinational pharmaceutical companies and leading global biotechnology companies. More importantly, these partnerships are not one-off transactions - they are evolving into a sustainable financial foundation that enables us to continuously discover and develop innovative biotherapeutics for patients worldwide. Looking ahead, we will build on this momentum through continued innovation and high-impact collaborations to deliver sustainable long-term growth."
[1] Adjusted items of profit are mainly from share-based compensation expenses and other one-time expenses.
Global Strategic Collaborations Fuel Continued Strong Revenue Growth
The Company's strong earnings growth was primarily driven by the continued execution and expansion of high-value strategic collaborations with global partners. Harbour BioMed has successfully transformed its proprietary technology platforms and licensing business into a robust and recurring revenue engine.
During the Reporting Period, several major strategic collaborations made significant contributions to revenue. In December 2025, the Company entered into a long-term global strategic collaboration with Bristol Myers Squibb (BMS) to jointly discover and develop next-generation multi-specific antibodies. Under the terms of the agreement, Harbour BioMed could receive payments totaling $90 million, as well as development and commercial milestones of up to $1.035 billion. The Company also expanded its strategic collaboration with AstraZeneca to include antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics. In addition, previously announced licensing partnerships with AstraZeneca, Otsuka, Pfizer, Windward Bio and other global pharmaceutical companies continued to generate meaningful revenue. To date, Harbour BioMed's proprietary technology platforms have been applied across more than 380 drug discovery programs spanning multiple therapeutic areas, with more than 20 molecules having advanced into IND-enabling studies or clinical development, reinforcing the Company's leadership in next-generation biologics innovation.
Beyond licensing collaboration, Nona Biosciences has entered a period of rapid growth. Revenue generated from its platform-based technology licensing and discovery services, together with milestone payments from existing collaborations, has become another important pillar of the Company's business. These collaborations not only reflect the strong recognition of the Harbour Mice® platform by multinational pharmaceutical companies, innovative biotechnology companies and leading academic institutions worldwide, but also underscore Harbour BioMed's successful transformation into a sustainable cash-generating business with enhanced financial resilience and a significantly strengthened risk profile.
Technology Platforms and AI Innovation Strengthen the Value Foundation
Harbour BioMed has embraced artificial intelligence (AI) as a core strategic priority, integrating AI technologies throughout the entire drug discovery and development process. In October 2025, the Company launched the first fully human AI-powered heavy-chain-only antibody (HCAb) generation and screening model enabled by its proprietary Hu-mAtrIx™ AI platform, establishing a closed-loop workflow encompassing AI-driven design, intelligent screening and experimental validation. The model has already demonstrated strong performance, achieving a target hit rate of 78.5%, significantly improving both discovery efficiency and developability.
During the same month, Harbour BioMed initiated the AI + Biopharmaceutical Ecosystem Alliance, bringing together organizations including Insilico Medicine, Molecule Mind and more to systematically transform the drug discovery process through AI-enabled innovation.
In May 2026, the Company reported encouraging preclinical data for LET003, its first next-generation ACVR2A/2B-targeting monoclonal antibody developed using the Hu-mAtrIx™ AI platform. In June 2026, Harbour BioMed further strengthened its AI strategy by entering into a comprehensive long-term strategic partnership with BioMap, a global leader in foundation AI models for life sciences. Together, the two companies established MegaStream TechBio, a joint venture dedicated to developing innovative AI-enabled drug pipelines for the global market. By integrating proprietary datasets, domain-specific foundation models and a broad portfolio of innovative programs, MegaStream TechBio aims to build a next-generation AI drug discovery engine centered on intelligent wet-lab/dry-lab integration and personalized, multimodal, multi-attribute generative AI models.
Clinical Pipeline Continues to Unlock Long-Term Value
Harbour BioMed continues to make meaningful progress across its differentiated pipeline. The Company now has nearly 30 innovative product candidates spanning immunology, oncology, obesity and metabolic diseases, and central nervous system (CNS) disorders—therapeutic areas with significant unmet medical needs. Multiple programs have advanced into clinical development.
For respiratory and immunological diseases, batoclimab, the Company's anti-FcRn monoclonal antibody, is the first drug in China to have completed the full clinical development pathway from Phase 1 through pivotal clinical trials. The biologics license application (BLA) has been submitted, and the therapy has the potential to become an important treatment option across multiple autoimmune diseases. Phase 1 data for the Company's ultra-long-acting anti-TSLP antibody HBM9378 demonstrated a substantially extended half-life, supporting the potential for twice-yearly dosing and reinforcing its best-in-class potential. Initial Phase 2 data in asthma are expected in the second half of 2026, while the Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) has already dosed its first patients. Meanwhile, another ultra-long-acting, TSLP-targeting bispecific antibody, HBM7575, has dosed the first subject in its Phase 1 study for atopic dermatitis and recently received IND clearance for the treatment of asthma.
For immuno-oncology, HBM4003, the Company's anti-CTLA-4 heavy-chain-only antibody, has demonstrated best-in-class potential. In a Phase 2 study in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), HBM4003 in combination with tislelizumab achieved an objective response rate (ORR) of 34.8% and a median progression-free survival (mPFS) of 4.2 months. Based on these encouraging results, the Company entered into a licensing agreement and equity partnership with Solstice Oncology in February 2026, receiving upfront consideration valued at over $105 million and being eligible for milestone payments of up to approximately US$1.1 billion.
In addition, the Company's HBM7004, a bispecific antibody for solid tumors, has received IND clearance from the U.S. Food and Drug Administration (FDA), while its IND application has been accepted by China's National Medical Products Administration (NMPA).
From its foundational proprietary technology platforms and AI-driven innovation to the advancement of a differentiated clinical pipeline and the execution of high-value global partnerships, Harbour BioMed has built a self-reinforcing innovation ecosystem. The Company's sustained profitability over multiple years demonstrates the successful execution of its unique business model, creating a virtuous cycle that converts technology innovation into long-term commercial value.
Looking ahead, supported by an expanding global partner network, a deeply integrated AI- and automation-enabled R&D platform, and a steadily advancing differentiated pipeline, Harbour BioMed is well positioned to continue delivering sustainable growth. With a strong financial foundation and industry-leading technological capabilities, the Company is evolving from a technology adopter to a technology leader, bringing more innovative antibody therapeutics to patients worldwide.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies.
By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
Statement
The information contained in this press release is only a preliminary assessment by the Board based on the unaudited management accounts of the Company and its subsidiaries for the six months ended June 30, 2026 currently available to the Company, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board, or reviewed or audited by the auditors of the Company. The actual results for the six months ended June 30, 2026 may differ from those disclosed in this press release. As such, the above figures are strictly for information only and not for any other purposes.
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
This announcement is made by HBM Holdings Limited (the “ Company ” , together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group. The board of directors of the Company (the “ Board ” ) is pleased to announce that the Investigational New Drug ( “ IND ” ) application for HBM7575 (also known as SKB575), a long-acting bispecific antibody targeting thymic stromal lymphopoietin ( “ TSLP ” ) and an undisclosed target for the treatment of asthma, has been approved by the National Medical Products Administration of China (the “NMPA”). This bispecific antibody was co-developed by Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech”) (6990.HK). Previously, the first participant has been dosed for the Phase I clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis. About HBM7575/SKB575 HBM7575/SKB575 is a long-acting bispecific antibody targeting TSLP and an undisclosed antigen, with a dual mechanism of action. On one hand, by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells. On the other hand, binding to and blocking the undisclosed target generates a synergistic effect, with the potential to achieve broader control of inflammation compared to single-target approaches. HBM7575/SKB575 has been engineered to allow for longer dosing intervals and a convenient subcutaneous route of administration. Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of more than three months, positioning it as a potential best-in-class therapy. According to the collaboration agreement between the Company and Kelun-Biotech, HBM7575/ SKB575 is led by Kelun-Biotech in its design, global development and commercialization, with the Company participating in the investment and development of this asset and sharing the benefits as agreed.
1
Cautionary Statement: We cannot guarantee that we or our collaboration partner will be able to successfully develop or ultimately market HBM7575/SKB575. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company. By order of the Board HBM Holdings Limited Dr. Jingsong Wang Chairman and Executive Director Hong Kong, 15 July 2026
As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.
2
Cambridge, MA, Rotterdam, NL, Shanghai, CN — July 15, 2026
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, and Kelun-Biotech (6990.HK) today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7575/SKB575, a long-acting bispecific antibody targeting thymic stromal lymphopoietin (TSLP) and an undisclosed target co-developed by the two parties, for the treatment of asthma. Previously, the first participant has been dosed in a Phase 1 clinical study of HBM7575/SKB575 for the treatment of atopic dermatitis.
Asthma is a chronic respiratory condition affecting approximately 300 million people worldwide, with prevalence continuing to rise. Despite the availability of treatment options, many patients experience persistent symptoms, frequent exacerbations, and reduced quality of life. Current therapies - mainly inhaled corticosteroids (ICS) and bronchodilators - are inadequate for some patients, underscoring the urgent need for more effective, long-acting treatments that address the underlying disease mechanisms.
"Building on the recent first participant dosing for HBM7575/SKB575 in atopic dermatitis, we are thrilled to see this molecule rapidly advancing into asthma indication." Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented. "With two major indications now cleared for clinical development, we look forward to executing our clinical plan and exploring the full potential of this molecule to redefine treatment paradigms for chronic immune-mediated conditions."
About HBM7575/SKB575
HBM7575/SKB575 is a long-acting bispecific antibody targeting TSLP and an undisclosed antigen, with a dual mechanism of action. On one hand, by blocking the interaction between TSLP and its receptor, it inhibits TSLP-mediated signaling pathways and the activation of Th2 immune cells. On the other hand, binding to and blocking the undisclosed target generates a synergistic effect, with the potential to achieve broader control of inflammation compared to single-target approaches. HBM7575/SKB575 has been engineered to allow for longer dosing intervals and a convenient subcutaneous route of administration. Based on preclinical half-life data, the anticipated human half-life is expected to support dosing intervals of more than three months, positioning it as a potential best-in-class therapy.
According to the collaboration agreement between Harbour BioMed and Kelun-Biotech, HBM7575/SKB575 is led by Kelun-Biotech in its design, global development and commercialization, with Harbour BioMed participating in the investment and development of this asset and sharing the benefits as agreed.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/ .
NEXT:
Professor Frank Grosveld, Inventor of the Harbour Mice® Platform, Passes Away
Newsroom

Follow
Harbour BioMed
on WeChat

Harbour BioMed
Single Cell Technology Platform
Fully Human Generative AI HCAb Model
Clinical Development & Medical Services
IND-IIT Bidirectional Drive Model
AI-Empowered Full Clinical Trial Lifecycle
An Efficient and Collaborative Organizational System
Inflammatory & Immunology Diseases
Notices-Replacement of Lost Share Certificates
Copyright © 2026 Harbour BioMed. All Rights Reserved | 沪公网安备 31011502019021号 沪ICP备19015946号
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
30 June 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
HBM Holdings Limited
Date Submitted:
07 July 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Not applicable
Number of authorised/registered shares Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Par value
20,000,000,000 USD 0 20,000,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 10
Yes
Authorised/registered share capital 0.000025 USD
500,000
USD
0
0.000025 USD
500,000 500,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Not applicable
Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Number of treasury shares
Yes
Total number of issued shares
867,607,722
31,834,000
734,000
0
868,341,722
31,834,000
899,441,722
900,175,722
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 10
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Post-IPO Share Option Scheme
35,400,700 Granted
Cancelled Lapsed
Listed on the Exchange (Note 1)
Number of share options outstanding at close of the month
Movement during the month
Exercised - new shares involved
General Meeting approval date (if applicable)
Not applicable
34,426,700
0
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
Yes
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
734,000
34,426,700
29,457,616
-734,000 0 -240,000
23 November 2020
Increase in issued shares (excluding treasury shares): Decrease in treasury shares: Total funds raised during the month from exercise of options: HKD
Page 3 of 10
734,000
Ordinary shares (AA1) Ordinary shares (AA2) 1,882,884
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 10
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 10
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Description of other agreements or arrangements
1).
Post-IPO Share Award Scheme
Not applicable
General Meeting approval date (if applicable)
Listed on the Exchange (Note 1)
Number of treasury shares transferred Number of shares which may be issued out of treasury during the month or transferred out of treasury pursuant pursuant thereto (D2) thereto as at close of the month
Number of new shares issued during the month pursuant thereto (D1)
23 November 2020
Yes
0
0
Increase in issued shares (excluding treasury shares):
0
Ordinary shares (DD1)
Decrease in treasury shares:
0
Ordinary shares (DD2)
Page 6 of 10
28,463,058
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description At price (if applicable)
Events Currency 1).
Repurchase of shares (shares repurchased for cancellation but not yet cancelled)
Not applicable
Date of event (Note 2)
Listed on the Exchange (Note 1)
General Meeting approval date (if applicable)
Increase/ decrease (-) in issued shares (excluding treasury shares) during the month pursuant thereto (E1)
Yes
Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)
Number of shares redeemed or repurchased for cancellation but not yet cancelled as at close of the month (Note 3)
Amount 06 June 2024
-406,000
Increase/ decrease (-) in issued shares (excluding treasury shares):
Ordinary shares (EE1)
Increase/ decrease (-) in treasury shares:
Ordinary shares (EE2)
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1):
734,000
Ordinary shares
Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
0
Ordinary shares
Page 7 of 10
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 8 of 10
v 1.2.1
FF301
V. Confirmations Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued, or the treasury shares sold or transferred by the issuer during the month as set out in Parts III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 5) (i) all money due to the listed issuer in respect of the issue of securities, or sale or transfer of treasury shares has been received by it; (ii) all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled; (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 6); (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements; (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.
Submitted by:
Jingsong Wang
Title:
Executive Director (Director, Secretary or other Duly Authorised Officer)
Page 9 of 10
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 10 of 10
v 1.2.1
At the annual general meeting (the “AGM”) of HBM Holdings Limited (the “Company”) held on 25 June 2026, all the proposed resolutions as set out in the notice of the AGM dated 28 April 2026 were duly passed by way of poll. The poll results are as follows: Number of Votes (%)
Ordinary Resolutions
For
Against
To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor of the Company for the year ended 31 December 2025.
397,716,082 (99.97%)
125,000 (0.03%)
To re-elect Dr. Yiping Rong as an executive director of the Company.
397,839,323 (99.99%)
1,759 (0.01%)
To re-elect Ms. Weiwei Chen as an independent non-executive director of the Company.
380,734,400 (95.70%)
17,106,682 (4.30%)
To authorise the board of directors of the Company to fix the remuneration of the directors of the Company.
397,692,082 (99.96%)
149,000 (0.04%)
To re-appoint Ernst & Young as auditor of the Company and authorise the board of directors of the Company to fix its remuneration.
397,841,082 (100.00%)
0 (0.00%)
1
Number of Votes (%)
Ordinary Resolutions
For
Against
To grant a general mandate to the directors of the Company to allot, issue and deal with additional shares (including any sale or transfer of shares out of treasury that are held as treasury shares) not exceeding 20% of the number of issued shares of the Company (excluding any treasury shares).
326,180,241 (81.99%)
71,660,841 (18.01%)
To grant a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the number of issued shares of the Company (excluding any treasury shares).
397,841,082 (100.00%)
0 (0.00%)
To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 6 to issue shares by adding the number of shares repurchased under ordinary resolution no. 7.
326,768,441 (82.14%)
71,072,641 (17.86%)
Notes: (a)
As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 8, all resolutions were duly passed as ordinary resolutions.
(b)
The total number of shares of the Company in issue as at the date of the AGM was 900,070,722 shares. 31,834,000 treasury shares of the Company were held or deposited with the Central Clearing and Settlement System as at 18 June 2026 and such treasury shares were excluded from the total number of issued shares of the Company entitling the holder to attend and vote on the resolutions at the AGM. A total of 55,000 ordinary shares of the Company were issued on 22, 23, 24 and 25 June 2026 to satisfy the share awards pursuant to the Post-IPO Share Award Scheme adopted by the shareholders of the Company on 23 November 2020 and such ordinary shares were excluded from the total number of issued shares of the Company entitling the holder to attend and vote on the resolutions at the AGM.
(c)
The trustee of the Post-IPO Share Award Scheme of the Company held unvested awards (representing 9,044,352 shares), and was required to abstain from voting on all the resolutions proposed at the AGM. Accordingly, the total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 859,137,370 shares. No voting rights of treasury shares have been exercised at the AGM. Save as disclosed, no shareholder of the Company was required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) to abstain from voting on the resolutions at the AGM.
(d)
There were no shares entitling the holder to attend but where the holder was required to abstain from voting in favour of any of the resolutions at the AGM as set out in Rule 13.40 of the Listing Rules.
(e)
None of the shareholders of the Company have stated their intention in the Company’s circular dated 28 April 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.
(f)
The Company ’ s branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
2
(g)
All directors (except Dr. Jingsong Wang, Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen who did not attend due to work commitments) attended the AGM in person or by electronic means.
By order of the Board HBM Holdings Limited Dr. Jingsong Wang Chairman and Executive Director Hong Kong, 25 June 2026
As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.
3
This announcement is made by HBM Holdings Limited (the “ Company ” , together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest updates in respect of the intellectual property protection efforts of the Group. The board of directors of the Company (the “Board”) wishes to inform the shareholders and potential investors of the Company that a jury in the United States District Court for the District of Delaware (the “Court”) has returned a verdict in favor of Harbour Antibodies BV (together with other related parties, “Harbour Antibodies”), a member of the Group, in the patent infringement lawsuit originally filed in 2021 against Amgen Inc. and Teneobio, Inc., an Amgen subsidiary (together, “Amgen”) (the “Litigation”). The Litigation relates to certain patents protecting the Group ’ s antibody discovery platform, a groundbreaking invention made by Professor Frank Grosveld, a founder of Harbour Antibodies (each a “ Grosveld Patent” and collectively, the “Grosveld Patents”). Following a jury trial which commenced on 8 June 2026, the jury found, among other things, that (i) Amgen infringed Grosveld Patent, (ii) the infringement was willful, (iii) the Grosveld Patent is valid, and (iv) Harbour Antibodies is entitled to damages of US$20,203,704, being the full amount requested at trial. The finding of willful infringement provides a basis for Harbour Antibodies to petition the Court for enhanced damages, which may include up to treble damages. If such enhanced damages are granted in full, the award could increase to up to approximately US$60.6 million. The Group will evaluate and, where appropriate, take further steps in respect of the verdict, potential enhanced damages and other proceedings relating to the Group’s broader patent portfolio.
1
The Company will make further announcement(s) on any material developments as and when appropriate in compliance with the Listing Rules. Cautionary Statement: Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. By order of the Board HBM Holdings Limited Dr. Jingsong Wang Chairman and Executive Director Hong Kong, 15 June 2026
As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.
2
This announcement is made by HBM Holdings Limited (the “ Company ” , together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board of directors of the Company (the “Board”) is pleased to announce that the Company and BioMap have entered into a multi-dimensional, long-term global strategic partnership centered on artificial intelligence ( “ AI ” )-driven discovery and development of complex biologics (the “Strategic Partnership”). The Strategic Partnership aims to systematically overcome the critical bottlenecks constraining next-generation innovative therapies and to build a globally competitive, AI-powered R&D ecosystem. Under the strategic collaboration framework, the Company and BioMap will jointly initiate MegaStream TechBio (“MegaStream”), a next-generation AI-native pipeline company targeting global markets. MegaStream is expected to integrate exclusive datasets, purpose-built large models and a large-scale innovative pipeline portfolio into an AI-powered research and development engine, enabled by an advanced integrated intelligent dry-wet closed loop discovery laboratory, paired with a partner-tailored, multimodal and multi-objective generative large model. MegaStream will focus on addressing critical unmet clinical needs across cardiovascular, renal, oncology and anti-aging disease areas, and will prioritize First-in-Class ( “ FIC ” ) and Best-in-Class ( “ BIC ” ) assets as its core development benchmarks. As the lead founding partner, the Company will grant MegaStream access to its proprietary fully human antibody platform, in-depth target biology know-how and global clinical development capabilities. BioMap, as co-founding partner, will contribute foundational AI technology, model engineering and intelligent research and development capabilities to accelerate pipeline development. MegaStream’s initial pipeline is expected to consist of AI-identified drug candidates from the parties’ earlier collaborations and newly launched AI-driven discovery programs. The founding parties are expected to be entitled to potential upfront payments, success-based milestone payments and royalty sharing in accordance with industry practice. In addition, MegaStream’s core management team is expected to be composed of seasoned executives from multinational biopharmaceutical companies and leading experts in artificial intelligence, with key appointments currently underway.
1
The Board believes that the Strategic Partnership represents a further advancement of the Group’s existing collaboration with BioMap and is expected to strengthen the Group ’s AI-enabled discovery engine, expand the application scenarios of the Group’s technology platforms and support the Group’s strategy of developing differentiated next-generation complex biologics. About BioMap BioMap is a global leader in AI foundation models for life sciences, dedicated to building next-generation AI infrastructure to accelerate scientific discovery across the industry. BioMap ’ s proprietary 268-billion-parameter life sciences foundation model family, xTrimo, learns the underlying rules governing genes, proteins, cells, and biological systems, delivering highly accurate AI-driven predictions. It has achieved state-of-the-art (SOTA) performance across more than 300 predictive tasks spanning over 20 life science subfields, and was awarded the championship title at the first global Virtual Cell Challenge. Built upon its foundation model, BioMap’s product BioMap OS is an AI-powered life sciences discovery system that enables users to establish systematic AI capabilities. Through AI-driven dry-wet closed-loop discovery, it supports data insights, parameter optimization, and de novo design, while empowering users to accumulate proprietary data and train their own AI models, continuously enhancing their AI capabilities over time. BioMap currently supports over 800 institutional users worldwide, spanning multiple verticals including antibody and protein, innovative therapies and precision medicine, synthetic biology, and frontier scientific research. Cautionary Statement: We cannot guarantee that any drug candidate will be successfully developed or ultimately marketed by the Company and/or its collaboration partners. Shareholders and potential investors of the Company are advised to exercise due care when dealing with the shares of the Company. Forward Looking Statement There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors. By order of the Board HBM Holdings Limited Dr. Jingsong Wang Chairman and Executive Director Hong Kong, 15 June 2026
As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.
2
This announcement is made by HBM Holdings Limited (the “ Company ” , together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group. The board of directors of the Company (the “Board”) is pleased to announce that the National Medical Products Administration of China (the “ NMPA ” ) has accepted the Investigational New Drug (“IND”) application for HBM7004, a novel B7H4xCD3 bispecific antibody, for the treatment of advanced solid tumors. This follows the Group’s recent receipt of clearance of its IND application from the Food and Drug Administration of the United States to initiate a first-in-human Phase I clinical trial in the U.S. for HBM7004, as disclosed in the Company’s announcement dated 8 May 2026. About HBM7004 HBM7004 is a novel B7H4xCD3 bispecific antibody developed using the Group’s proprietary HBICE® platform. This bispecific antibody is designed to provide a differentiated approach to cancer immunotherapy with the potential to enhance both efficacy and safety. The development of HBM7004 further demonstrates the versatility and plug-and-play advantages of the HBICE® platform. In preclinical studies, HBM7004 demonstrated intratumor B7H4-dependent T-cell activation. In multiple animal models, HBM7004 showed strong anti-tumor efficacy, remarkable in vivo stability, and reduced systemic toxicity. Additionally, in preclinical models, HBM7004 exhibited a strong synergistic effect when combined with a B7H4x4-1BB bispecific antibody at a low effector-to-target cell ratio, indicating an encouraging therapeutic window.
1
Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM7004. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company. By order of the Board HBM Holdings Limited Dr. Jingsong Wang Chairman and Executive Director Hong Kong, 10 June 2026
As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.
2
This announcement is made by HBM Holdings Limited (the “ Company ” , together with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group. The board of directors of the Company (the “Board”) is pleased to announce that Windward Bio AG (“Windward Bio”), the Company’s partner, has dosed the first patients in the Phase II SIRIUS study of HBM9378/WIN378 (also known as SKB378), a fully human ultra long-acting anti-thymic stromal lymphopoietin (TSLP) antibody, in patients with chronic obstructive pulmonary disease (COPD). SIRIUS is a global, Phase II, randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HBM9378/WIN378 in patients with moderate-to-severe COPD. HBM9378/WIN378 is currently also being evaluated in Windward Bio’s POLARIS Phase II/III asthma study, with initial Phase II data expected in the second half of 2026. Windward Bio expects the first Phase III study of HBM9378/WIN378 in asthma to begin in the fourth quarter of 2026. The initiation of the SIRIUS COPD study expands the clinical development of HBM9378/WIN378 into COPD as a second major respiratory disease. The Board believes that the initiation of the SIRIUS COPD study marks continued clinical advancement of HBM9378/WIN378 and further supports the potential of the molecule as a differentiated, ultra long-acting anti-TSLP antibody for immunological diseases.
1
About HBM9378/WIN378 HBM9378/WIN378 (also known as SKB378) is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. HBM9378/WIN378 has been engineered to achieve half-life extension (HLE) and have a silenced effector function. It has been studied in a Phase I trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. HBM9378/WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Harbour BioMed (also known as HBM9378) and Kelun-Biotech (also known as SKB378). HBM9378/WIN378 is currently being evaluated in the POLARIS Phase II/III asthma study with initial readouts expected in the second half of 2026. HBM9378/WIN378 is also being evaluated in the SIRIUS Phase II COPD study. The first Phase III study of HBM9378/WIN378 in asthma is expected to begin in the fourth quarter of 2026. Cautionary Statement: We cannot guarantee that HBM9378/WIN378 will be successfully developed or ultimately marketed by the Company and/or its collaboration partners. Shareholders and potential investors of the Company are advised to exercise due care when dealing with the shares of the Company. Forward Looking Statement There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors. By order of the Board HBM Holdings Limited Dr. Jingsong Wang Chairman and Executive Director Hong Kong, 9 June 2026
As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.
2
FF301
Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities For the month ended:
31 May 2026
Status: New Submission
To : Hong Kong Exchanges and Clearing Limited Name of Issuer:
HBM Holdings Limited
Date Submitted:
04 June 2026
I. Movements in Authorised / Registered Share Capital
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Not applicable
Number of authorised/registered shares Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Par value
20,000,000,000 USD 0 20,000,000,000 USD Total authorised/registered share capital at the end of the month: USD
Page 1 of 11
Yes
Authorised/registered share capital 0.000025 USD
500,000
USD
0
0.000025 USD
500,000 500,000
v 1.2.1
FF301
II. Movements in Issued Shares and/or Treasury Shares and Public Float Sufficiency Confirmation
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Not applicable
Number of issued shares (excluding treasury shares) Balance at close of preceding month Increase / decrease (-) Balance at close of the month
Listed on the Exchange (Note 1)
Number of treasury shares
Yes
Total number of issued shares
872,842,722
25,937,000
-5,235,000
5,897,000
867,607,722
31,834,000
898,779,722
899,441,722
Public float sufficiency confirmation (Note 4) Pursuant to Main Board Rule 13.32D(1) or 19A.28D(1) / GEM Rule 17.37D(1) or 25.21D(1), we hereby confirm that, in relation to the class of shares as set out above, as at the close of the month: ✔ the applicable public float requirement (see below) has been complied with the applicable public float requirement (see below) has not been complied with The applicable minimum public float requirement for the class of shares as set out above pursuant to Main Board Rule 13.32B or 19A.28B / GEM Rule 17.37B or 25.21B (as the case may be) is: Applicable public float threshold
Initial Prescribed Threshold - 25% of the total number of issued shares in the class to which the listed shares belong (excluding treasury shares)
Additional information
Page 2 of 11
v 1.2.1
FF301
III. Details of Movements in Issued Shares and/or Treasury Shares (A). Share Options (under Share Option Schemes of the Issuer)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Particulars of share option scheme
1).
Number of share options outstanding at close of preceding month
Post-IPO Share Option Scheme
36,062,700 Granted
Listed on the Exchange (Note 1)
Number of share options outstanding at close of the month
Movement during the month
Exercised - new shares involved
General Meeting approval date (if applicable)
Not applicable
35,400,700
0
Number of treasury Number of new shares shares transferred out of issued during the month treasury during the pursuant thereto (A1) month pursuant thereto (A2)
Yes
The total number of Number of shares which shares which may be may be issued or issued or transferred out transferred out of of treasury upon treasury pursuant exercise of all share thereto as at close of options to be granted the month under the scheme at close of the month
662,000
35,400,700
29,217,616
-662,000
Cancelled
0
Lapsed
0
23 November 2020
Increase in issued shares (excluding treasury shares): Decrease in treasury shares: Total funds raised during the month from exercise of options: HKD
Page 3 of 11
662,000
Ordinary shares (AA1) Ordinary shares (AA2) 2,102,610
v 1.2.1
FF301 (B). Warrants to Issue Shares of the Issuer
Not applicable
Page 4 of 11
v 1.2.1
FF301 (C). Convertibles (i.e. Convertible into Shares of the Issuer)
Not applicable
Page 5 of 11
v 1.2.1
FF301 (D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Description of other agreements or arrangements
1).
Post-IPO Share Award Scheme
Not applicable
General Meeting approval date (if applicable)
Listed on the Exchange (Note 1)
Number of treasury shares transferred Number of shares which may be issued out of treasury during the month or transferred out of treasury pursuant pursuant thereto (D2) thereto as at close of the month
Number of new shares issued during the month pursuant thereto (D1)
23 November 2020
Yes
0
0
Increase in issued shares (excluding treasury shares):
0
Ordinary shares (DD1)
Decrease in treasury shares:
0
Ordinary shares (DD2)
Page 6 of 11
28,383,058
v 1.2.1
FF301 (E). Other Movements in Issued Shares and/or Treasury Shares
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Not applicable
At price (if applicable) Events Currency
Date of event (Note 2)
Listed on the Exchange (Note 1)
General Meeting approval date (if applicable)
Increase/ decrease (-) in issued shares (excluding treasury shares) during the month pursuant thereto (E1)
Yes
Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)
Number of shares redeemed or repurchased for cancellation but not yet cancelled as at close of the month (Note 3)
Amount
1).
Repurchase of shares (shares repurchased for cancellation but not yet cancelled)
2).
Repurchase of shares (shares held as treasury shares)
HKD
12.99878
04 May 2026
11 June 2025
-500,000
500,000
3).
Repurchase of shares (shares held as treasury shares)
HKD
12.941
05 May 2026
11 June 2025
-300,000
300,000
4).
Repurchase of shares (shares held as treasury shares)
HKD
12.84163
06 May 2026
11 June 2025
-800,000
800,000
5).
Repurchase of shares (shares held as treasury shares)
HKD
13.28061
07 May 2026
11 June 2025
-33,000
33,000
6).
Repurchase of shares (shares held as treasury shares)
HKD
13.239
08 May 2026
11 June 2025
-300,000
300,000
7).
Repurchase of shares (shares held as treasury shares)
HKD
13.07372
11 May 2026
11 June 2025
-164,000
164,000
8).
Repurchase of shares (shares held as treasury shares)
HKD
13.21967
12 May 2026
11 June 2025
-300,000
300,000
9).
Repurchase of shares (shares held as treasury shares)
HKD
12.74
13 May 2026
11 June 2025
-700,000
700,000
10). Repurchase of shares (shares held as treasury shares)
HKD
12.75535
14 May 2026
11 June 2025
-400,000
400,000
11). Repurchase of shares (shares held as treasury shares)
HKD
12.71553
15 May 2026
11 June 2025
-400,000
400,000
12). Repurchase of shares (shares held as treasury shares)
HKD
12.51173
18 May 2026
11 June 2025
-1,000,000
1,000,000
13). Repurchase of shares (shares held as treasury shares)
HKD
12.30896
19 May 2026
11 June 2025
-500,000
500,000
14). Repurchase of shares (shares held as treasury shares)
HKD
11.89207
20 May 2026
11 June 2025
-300,000
300,000
15). Repurchase of shares (shares held as treasury shares)
HKD
11.9232
21 May 2026
11 June 2025
-200,000
200,000
06 June 2024
-406,000
Increase/ decrease (-) in issued shares (excluding treasury shares):
-5,897,000
Ordinary shares (EE1)
Increase/ decrease (-) in treasury shares:
5,897,000
Ordinary shares (EE2)
Total increase/ decrease (-) in issued shares (excluding treasury shares) during the month (i.e. Total of AA1 to EE1): Page 7 of 11
-5,235,000
Ordinary shares v 1.2.1
FF301 Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):
Page 8 of 11
5,897,000
Ordinary shares
v 1.2.1
FF301
IV. Information about Hong Kong Depositary Receipt (HDR)
Not applicable
Page 9 of 11
v 1.2.1
FF301
V. Confirmations Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued, or the treasury shares sold or transferred by the issuer during the month as set out in Parts III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 5) (i) all money due to the listed issuer in respect of the issue of securities, or sale or transfer of treasury shares has been received by it; (ii) all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled; (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 6); (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements; (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.
Submitted by:
Jingsong Wang
Title:
Executive Director (Director, Secretary or other Duly Authorised Officer)
Page 10 of 11
v 1.2.1
FF301 Notes 1.
The Exchange refers to The Stock Exchange of Hong Kong Limited.
In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date". In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".
The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
"Initial Prescribed Threshold”, "Alternative Threshold” and "market value" have the meanings ascribed thereto under Main Board Rule 13.32A or 19A.28A / GEM Rule 17.37A or 25.21A. See also Main Board Rule 13.32D(4) or 19A.28D(4) / GEM Rule 17.37D(4) or 25.21D(4) on the basis of the public float disclosure.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
“Identical” means in this context: .
the securities are of the same nominal value with the same amount called up or paid up;
.
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
.
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 11 of 11
v 1.2.1
(Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares) Instrument:
Equity issuer
Name of Issuer:
HBM Holdings Limited
Date Submitted:
21 May 2026
Status:
New Submission
Section I must be completed by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”) (the “Main Board Rules”) or rule 17.27A of the Rules Governing the Listing of Securities on GEM of the Exchange (the “GEM Rules”). Section I
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Listed on the Exchange
Not applicable
Yes
A. Changes in issued shares or treasury shares Changes in issued shares (excluding treasury shares) Events
Opening balance as at (Note 1) 1).
20 May 2026
Repurchase of shares (shares held as treasury shares) Date of changes
Changes in treasury shares
As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3)
Number of issued shares (excluding treasury shares)
867,677,722 -200,000
Number of treasury shares
Issue/ selling price per share (Note 4)
31,634,000 0.023 %
200,000 HKD
Total number of issued shares
899,311,722 11.9232
21 May 2026
Page 1 of 7
v 1.3.0
FF305 2).
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
46,000
0.0053 %
HKD
0
Issuance of ordinary shares to satisfy the share awards pursuant to the Post-IPO Share Award Scheme adopted by the shareholders of the Company on 23 November 2020 Date of changes
21 May 2026
Closing balance as at (Notes 5 and 6) 21 May 2026
867,523,722
31,834,000
899,357,722
B. Shares redeemed or repurchased for cancellation but not yet cancelled as at the closing balance date (Notes 5 and 6) 1).
Shares repurchased for cancellation but not yet cancelled Date of changes
2).
0.0327 %
HKD
2.25
156,000
0.0204 %
HKD
2.39468
08 January 2025
Shares repurchased for cancellation but not yet cancelled Date of changes
250,000
10 January 2025
Page 2 of 7
v 1.3.0
FF305 Confirmation Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 7) (i)
all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
(ii)
all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
(iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 8); (v)
all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
(vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies. Notes to Section I: 1.
Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.
Page 3 of 7
v 1.3.0
FF305 4.
In the case of a share repurchase or redemption, the “issue/ selling price per share” shall be construed as “repurchase price per share” or “redemption price per share”. Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
The closing balance date is the date of the last relevant event being disclosed.
For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled. If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 4 of 7
v 1.3.0
FF305 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).
Repurchase report Section II
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
A.
Yes
Repurchase report Trading date
1).
Listed on the Exchange
Not applicable
21 May 2026
Total number of shares repurchased Number of shares repurchased for cancellation Number of shares repurchased for holding as treasury shares
Number of shares repurchased
Method of repurchase (Note 1)
200,000 On the Exchange
Repurchase price per share or highest repurchase price per share $ HKD
Lowest repurchase price per share $
12.19 HKD
200,000
Aggregate price paid $ 11.7 HKD
2,384,640
Aggregate price paid $ HKD
2,384,640
0
200,000
B.
Additional information for issuer who has a primary listing on the Exchange
1).
Date of the resolution granting the repurchase mandate
2).
Total number of shares which the issuer is authorised to repurchase under the repurchase mandate
3).
Number of shares repurchased on the Exchange or another stock exchange under the repurchase mandate
4).
As a % of number of issued shares (excluding treasury shares) as at the date of the resolution granting the repurchase mandate (a) x 100 / number of issued shares (excluding treasury shares) as at the date of the resolution granting the repurchase mandate
5).
Moratorium period for any issue of new shares, or sale or transfer of treasury shares after the share repurchase(s) set out in Part A (Note 2)
11 June 2025 82,834,612 (a)
13,497,000 1.63 %
Up to
20 June 2026
We hereby confirm that the repurchases made on the Exchange set out in Part A above were made in accordance with the Main Board Rules / GEM Rules and that there have been no material changes to the particulars contained in the Explanatory Statement dated 22 April 2025 which has been filed with the Exchange. We also confirm that any repurchases made on another stock Page 5 of 7
v 1.3.0
FF305 exchange set out in Part A above were made in accordance with the domestic rules applying to repurchases on that other stock exchange.
Notes to Section II: 1.
Please state whether the repurchase was made on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.
Subject to the carve-out set out in Main Board Rule 10.06(3)(a)/ GEM Rule 13.12, an issuer may not (i) make a new issue of shares, or a sale or transfer of any treasury shares; or (ii) announce a proposed new issue of shares, or a sale or transfer of any treasury shares, for a period of 30 days after any purchase by it of shares, whether on the Exchange or otherwise, without the prior approval of the Exchange.
Page 6 of 7
v 1.3.0
FF305 Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.
Report of on-market sale of treasury shares
Not applicable
Submitted by: Jingsong Wang (Name) Title: Executive Director (Director, Secretary or other Duly Authorised Officer)
Page 7 of 7
v 1.3.0
(Equity issuer - changes in issued shares or treasury shares, share buybacks and/or on-market sales of treasury shares) Instrument:
Equity issuer
Name of Issuer:
HBM Holdings Limited
Date Submitted:
20 May 2026
Status:
New Submission
Section I must be completed by a listed issuer where there has been a change in its issued shares or treasury shares which is discloseable pursuant to rule 13.25A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Exchange”) (the “Main Board Rules”) or rule 17.27A of the Rules Governing the Listing of Securities on GEM of the Exchange (the “GEM Rules”). Section I
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
Listed on the Exchange
Not applicable
Yes
A. Changes in issued shares or treasury shares Changes in issued shares (excluding treasury shares) Events
Opening balance as at (Note 1) 1).
19 May 2026
Repurchase of shares (shares held as treasury shares) Date of changes
Changes in treasury shares
As a % of existing number of issued shares (excluding treasury shares) before the relevant event (Note 3)
Number of issued shares (excluding treasury shares)
867,961,722 -300,000
Number of treasury shares
Issue/ selling price per share (Note 4)
31,334,000 0.0346 %
300,000 HKD
Total number of issued shares
899,295,722 11.89207
20 May 2026
Page 1 of 7
v 1.3.0
FF305 2).
Issue of new shares or transfer of treasury shares in respect of share awards or options granted to a participant (who is not a director of the issuer) under a share scheme - new shares involved
16,000
0.0018 %
HKD
0
Issuance of ordinary shares to satisfy the share awards pursuant to the Post-IPO Share Award Scheme adopted by the shareholders of the Company on 23 November 2020 Date of changes
20 May 2026
Closing balance as at (Notes 5 and 6) 20 May 2026
867,677,722
31,634,000
899,311,722
B. Shares redeemed or repurchased for cancellation but not yet cancelled as at the closing balance date (Notes 5 and 6) 1).
Shares repurchased for cancellation but not yet cancelled Date of changes
2).
0.0327 %
HKD
2.25
156,000
0.0204 %
HKD
2.39468
08 January 2025
Shares repurchased for cancellation but not yet cancelled Date of changes
250,000
10 January 2025
Page 2 of 7
v 1.3.0
FF305 Confirmation Pursuant to Main Board Rule 13.25C / GEM Rule 17.27C, we hereby confirm to the best knowledge, information and belief that, in relation to each issue of shares or sale or transfer of treasury shares as set out in Section I, it has been duly authorised by the board of directors of the listed issuer and carried out in compliance with all applicable listing rules, laws and other regulatory requirements and, insofar as applicable: (Note 7) (i)
all money due to the listed issuer in respect of the issue of shares, or sale or transfer of treasury shares has been received by it;
(ii)
all pre-conditions for the listing imposed by the Main Board Rules / GEM Rules under "Qualifications of listing" have been fulfilled;
(iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled; (iv) all the securities of each class are in all respects identical (Note 8); (v)
all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with all other legal requirements;
(vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue, sale or transfer; (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies. Notes to Section I: 1.
Please insert the closing balance date of the last Next Day Disclosure Return published pursuant to Main Board Rule 13.25A / GEM Rule 17.27A or Monthly Return pursuant to Main Board Rule 13.25B / GEM Rule 17.27B, whichever is the later.
Please set out all changes in issued shares or treasury shares requiring disclosure pursuant to Main Board Rule 13.25A / GEM Rule 17.27A together with the relevant dates of changes. Each category will need to be disclosed individually with sufficient information to enable the user to identify the relevant category in the listed issuer's Monthly Return. For example, multiple issues of shares as a result of multiple exercises of share options under the same share option scheme or of multiple conversions under the same convertible note must be aggregated and disclosed as one category. However, if the issues resulted from exercises of share options under 2 share option schemes or conversions of 2 convertible notes, these must be disclosed as 2 separate categories.
The percentage change in the number of issued shares (excluding treasury shares) of the listed issuer is to be calculated by reference to the opening balance of the number of issued shares (excluding treasury shares) being disclosed in this Next Day Disclosure Return.
Page 3 of 7
v 1.3.0
FF305 4.
In the case of a share repurchase or redemption, the “issue/ selling price per share” shall be construed as “repurchase price per share” or “redemption price per share”. Where shares have been issued/ sold/ repurchased/ redeemed at more than one price per share, a volume-weighted average price per share should be given.
The closing balance date is the date of the last relevant event being disclosed.
For repurchase or redemption of shares, disclosure is required when the relevant event has occurred (subject to the provisions of Main Board Rules 10.06(4)(a), 13.25A and 13.31 / GEM Rules 13.13(1), 17.27A and 17.35), even if the repurchased or redeemed shares have not yet been cancelled. If repurchased or redeemed shares are to be cancelled upon settlement of such repurchase or redemption after the closing balance date, they shall remain part of the issued shares as at the closing balance date in Part A. Details of these repurchased or redeemed shares shall be disclosed in Part B.
Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases.
“Identical” means in this context:
the securities are of the same nominal value with the same amount called up or paid up;
they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
Page 4 of 7
v 1.3.0
FF305 Section II must also be completed by a listed issuer where it has made a repurchase of shares which is discloseable under Main Board Rule 10.06(4)(a) / GEM Rule 13.13(1).
Repurchase report Section II
- Class of shares
Ordinary shares
Type of shares
Stock code (if listed)
02142
Description
A.
Yes
Repurchase report Trading date
1).
Listed on the Exchange
Not applicable
20 May 2026
Total number of shares repurchased Number of shares repurchased for cancellation Number of shares repurchased for holding as treasury shares
Number of shares repurchased
Method of repurchase (Note 1)
300,000 On the Exchange
Repurchase price per share or highest repurchase price per share $ HKD
Lowest repurchase price per share $
12.29 HKD
300,000
Aggregate price paid $ 11.8 HKD
3,567,620
Aggregate price paid $ HKD
3,567,620
0
300,000
B.
Additional information for issuer who has a primary listing on the Exchange
1).
Date of the resolution granting the repurchase mandate
2).
Total number of shares which the issuer is authorised to repurchase under the repurchase mandate
3).
Number of shares repurchased on the Exchange or another stock exchange under the repurchase mandate
4).
As a % of number of issued shares (excluding treasury shares) as at the date of the resolution granting the repurchase mandate (a) x 100 / number of issued shares (excluding treasury shares) as at the date of the resolution granting the repurchase mandate
5).
Moratorium period for any issue of new shares, or sale or transfer of treasury shares after the share repurchase(s) set out in Part A (Note 2)
11 June 2025 82,834,612 (a)
13,297,000 1.605 %
Up to
19 June 2026
We hereby confirm that the repurchases made on the Exchange set out in Part A above were made in accordance with the Main Board Rules / GEM Rules and that there have been no material changes to the particulars contained in the Explanatory Statement dated 22 April 2025 which has been filed with the Exchange. We also confirm that any repurchases made on another stock Page 5 of 7
v 1.3.0
FF305 exchange set out in Part A above were made in accordance with the domestic rules applying to repurchases on that other stock exchange.
Notes to Section II: 1.
Please state whether the repurchase was made on the Exchange, on another stock exchange (stating the name of the exchange), by private arrangement or by general offer.
Subject to the carve-out set out in Main Board Rule 10.06(3)(a)/ GEM Rule 13.12, an issuer may not (i) make a new issue of shares, or a sale or transfer of any treasury shares; or (ii) announce a proposed new issue of shares, or a sale or transfer of any treasury shares, for a period of 30 days after any purchase by it of shares, whether on the Exchange or otherwise, without the prior approval of the Exchange.
Page 6 of 7
v 1.3.0
FF305 Section III must also be completed by a listed issuer where it has made a sale of treasury shares on the Exchange or any other stock exchange on which the issuer is listed which is discloseable under Main Board Rule 10.06B / GEM Rule 13.14B.
Report of on-market sale of treasury shares
Not applicable
Submitted by: Jingsong Wang (Name) Title: Executive Director (Director, Secretary or other Duly Authorised Officer)
Page 7 of 7
v 1.3.0
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Hbm Holdings Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DFEM | 0.01% | 435,000 | $ 606.643K | Nov 12, 2026 |